Mochizuki, Lyka
Gleicher, Norbert
Funding for this research was provided by:
Foundation for Reproductive Medicine (none)
Article History
Received: 29 July 2019
Accepted: 3 January 2020
First Online: 26 March 2020
Compliance with ethical standards
:
: L.M. has no competing interests to report but has joined <i>The CHR</i> as a research fellow. N.G. is President of <i>The Foundation for Reproductive Medicine</i> in New York, NY, a not-for-profit research foundation that hosted the externship of L.M. and supported her research. N.G. is also the owner of a for-profit fertility center, <i>The CHR</i> in New York, NY. He is a co-inventor on several pending and already awarded US patents claiming therapeutic benefits from androgen supplementation in women with low functional ovarian reserve and relating to the <i>FMR1</i> gene in diagnostic functions in female fertility. He receives royalties from Fertility Nutraceuticals, LLC, in which N.G. also holds shares. He is also a co-inventor on three pending AMH-related patent applications and in the past received research grants, travel funds, and/or speaker honoraria from Pharma and/or medical device companies, though none in any way related to hear presented materials. Neither author has commercial interests, relating to PGS/PGT-A.